Daunorubicin
Back to searchMolecule Structure
Scientific Name
Daunorubicin
Description of the Drug
Daunorubicin is an anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00694
http://www.drugbank.ca/drugs/DB00694
Brand Name(s)
Daunoxome
Company Owner(s)
Hisun Pharmaceutical Hangzhou Co Ltd, Fresenius Kabi Usa Llc, Wyeth Ayerst Research, Celator Pharmaceuticals Inc, Galen Ltd, Teva Parenteral Medicines Inc, Sanofi Aventis Us Llc, Teva Pharmaceuticals Usa, Hikma Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA topoisomerase II alpha | SINGLE PROTEIN | INHIBITOR | CHEMBL1806 |
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3041 | |||||||||||
| PharmGKB | PA449212 | |||||||||||
| Human Metabolome Database | HMDB0014832 | |||||||||||
| DrugBank | DB00694 | |||||||||||
| PubChem: Thomson Pharma | 14763056 | 15481415 | ||||||||||
| PubChem | 30323 | |||||||||||
| NMRShiftDB | 60022097 | |||||||||||
| LINCS | LSM-2962 | |||||||||||
| Nikkaji | J3.149F | |||||||||||
| PDBe | DM1 | |||||||||||
| BindingDB | 32017 | 50368352 | ||||||||||
| EPA CompTox Dashboard | DTXSID7022883 | |||||||||||
| LipidMaps | LMPK13050002 | |||||||||||
| DrugCentral | 786 | |||||||||||
| Metabolights | MTBLC41977 | |||||||||||
| Brenda | 10631 | 1532 | 48970 | 229359 | 229357 | 48969 | 229360 | 229358 | 48971 | 21578 | 96463 | 249524 |
| ChemicalBook | CB0338996 | |||||||||||
| Guide to Pharmacology | 7063 | |||||||||||
| rxnorm | DAUNORUBICIN CITRATE | DAUNORUBICIN | DAUNORUBICIN HYDROCHLORIDE | |||||||||
| PubChem: Drugs of the Future | 125299287 | |||||||||||
| KEGG Ligand | C01907 | |||||||||||
| ChEBI | 41977 | |||||||||||
| ZINC | ZINC000003917708 |
